ArticleJACC. Case reports2026
Transcatheter Aortic Valve Replacement in a Failed Homograft.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How to Plan a Transcatheter Aortic Valve Replacement in a Failed Aortic Homograft.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical reintervention for degenerated aortic homografts is associated with high operative risk. Transcatheter aortic valve replacement (TAVR) offers a less invasive alternative but is technically challenging with current-generation devices. CASE SUMMARY: A 72-year-old man with history of aortic homograft replacement presented with acute dyspnea due to severe aortic regurgitation (AR). Valve-in-valve TAVR was performed (29-mm Evolut FX+), with mild paravalvular AR. Subsequent transesophageal echocardiography revealed supra-annular valve position with a prolapsing, uncovered homograft leaflet, causing recurrent severe AR. Bailout redo-TAVR was performed (26-mm Sapien S3 Ultra) with intentional deployment at a deeper position, leading to successful AR resolution. DISCUSSION: This case demonstrates the technical difficulties with TAVR in failed aortic homografts, especially when the failure mechanism is AR. Owing to lack of leaflet calcification and difficulty with visualization, TAVR using commercial devices is associated with risk of valve malposition and need for a second valve. TAKE-HOME MESSAGE: Dedicated TAVR devices for AR will likely become the preferred treatment for failed homografts after commercial approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.